Cellomics and BD Sign License Agreement to Further Expand Availability of High Content Screening
Cellomics, Inc., the creator of High Content Screening (HCS), and global medical technology company BD (Becton, Dickinson and Company), through its BD Biosciences unit, announced that they have entered into a non-exclusive, worldwide patent license agreement. The agreement will provide BD with Cellomics' core High Content Screening patent portfolio that includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. Financial details of the agreement were not disclosed.
"We are very pleased to be working with BD to further expand the adoption and availability of high content screening technology. Through licensing of our HCS patent portfolio, we are seeking to enable customers to more effectively address complex biological questions," commented William T. Sharp, Cellomics' Vice President of Business Development.
"With the recent acquisition of Atto Biosciences, and our licensing of this intellectual property from Cellomics, BD Biosciences extends our commitment to the area of high-content cellular analysis and strengthens our considerable capabilities in the area of live cell research that include high-resolution imaging, flow cytometry and a broad array of reagent systems," added Mark Lewis, Vice President of BD Biosciences.
"Completion of this second significant licensing arrangement of our HCS patent portfolio with a global company like BD confirms the value of our extensive intellectual property in this critical area of drug discovery and reaffirms our intent to facilitate the expansion of the HCS market via an aggressive licensing and commercial strategy," stated Daniel J. Calvo, Cellomics' President and CEO.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
